| Code | CSB-RA017647MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ebronucimab, targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a secreted serine protease that plays a critical role in cholesterol homeostasis by binding to low-density lipoprotein receptors (LDLR) on hepatocyte surfaces, promoting their degradation and preventing recycling. This mechanism reduces the liver's ability to clear LDL cholesterol from circulation, making PCSK9 a significant therapeutic target in cardiovascular disease research. Elevated PCSK9 levels are associated with hypercholesterolemia, atherosclerosis, and increased cardiovascular risk.
Ebronucimab represents a novel class of PCSK9 inhibitors designed to block PCSK9-LDLR interaction, thereby preserving LDLR expression and enhancing LDL cholesterol clearance. This biosimilar antibody provides researchers with a valuable tool for investigating PCSK9 biology, lipid metabolism pathways, and cardiovascular disease mechanisms. It supports studies exploring cholesterol regulation, receptor trafficking, and potential therapeutic interventions for dyslipidemia and atherosclerotic conditions in preclinical models.
There are currently no reviews for this product.